© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to March
CNS pen. GPR6 GPCR inverse agonist
oral QD Ph. II candidate for ParkinsonÕs
from 360k cmpd cell-based HTS + opt.
J. Pharmacol. Exp. Ther., Apr. 1, 2021
Cerevance / Takeda California, San Diego, US
The Cerevance/Takeda GPR6 inverse agonist (CVN424) is an oral, once-daily clinical candidate in Ph. II for Parkinson’s disease after completing a Ph. I in healthy volunteers. Its >40 µM…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.